TWST
Undervalued by 19.6% based on the discounted cash flow analysis.
Market cap | $2.08 Billion |
---|---|
Enterprise Value | $1.95 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-3.6 |
Beta | 2.37 |
Outstanding Shares | 59,649,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -10.81 |
---|---|
PEG | 79.78 |
Price to Sales | 7.07 |
Price to Book Ratio | 5.05 |
Enterprise Value to Revenue | 5.6 |
Enterprise Value to EBIT | -12.96 |
Enterprise Value to Net Income | -11 |
Total Debt to Enterprise | 0.04 |
Debt to Equity | 0.18 |
No data
No data
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...